参考文献
1.邹万忠.肾活检病理学.第2版.北京：北京大学医学出版社，2009：93-107.
2. Weening JJ，D’Agati VD，Schwartz MM，et al.The classification of glomerulonephritis in systemic lupus erythematosus revisited.Kidney Int，2004，65：521-530.
3. Kidney Disease：Improving Global Outcomes（KDIGO）Glomerulonephritis Work Group.KDIGO clinical practice guideline for glomerulonephritis.Kidney Int Suppl，2012，2：139-274.
4. Hahn BH，McMahon MA，Wilkinson A，et al. American College of Rheumatology.American College of Rheumatology guidelines for screening，treatment，and management of lupus nephritis. Arthritis Care Res（Hoboken），2012，64 （6）：797-808.
5. Bertsias GK，Tektonidou M，Amoura Z，et al. European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association（EULAR/ERA-EDTA）recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis，2012，71（11）：1771-1782.
6. Borchers AT，Leibushor N，Naguwa SM，et al.Lupus nephritis：a critical review.Autoimmun Rev，2012，12（2）：174-194.
7. Sprangers B，Monahan M，Appel GB.Diagnosis and treatment of lupus nephritis flares—an update.Nat Rev Nephrol，2012，8（12）：709-717.
8. Najafi CC，Korbet SM，Lewis EJ，et al.Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis.Kidney Int，2001，59：2156-2163.
9. Hill GS，Delahousse M，Nochy D，et al.Class IV-S versus class IV-G lupus nephritis：clinical and morphologic differences suggesting different pathogenesis.Kidney Int，2005，68：2288-2297.
10. Mittal B，Hurwitz S，Rennke H，et al.New subcategories of classⅣlupus nephritis：are there clinical，histologic，and outcome differences？Am J Kidney Dis，2004，44：1050-1059.
11. Yu F，Tan Y，Wu LH，et al.Class IV-G and IV-S lupus nephritis in Chinese patients：a large cohort study from a single center.Lupus，2009，18：1073-1081.
12. Hiramatsu N，Kuroiwa T，Ikeuchi H，et al.Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions. Rheumatology（Oxford），2008，47：702-707.
13. Fu SM，Deshmukh US，Gaskin F.Pathogenesis of systemic lupus erythematosus revisited 2011：end organ resistance to damage，autoantibody initiation and diversification，and HLA-DR.J Autoimmun，2011，37：104-112.
14. Scheinecker C，Bonelli M，Smolen JS. Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells.J Autoimmun，2010，35：269-275.
15. Nowling TK，Gilkeson GS.Mechanisms of tissue injury in lupus nephritis.Arthritis Res Ther，2011，13：250.
16. Sato N，Ohsawa I，Nagamachi S，et al.Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis.Lupus，2011，20：1378-1386.
17. Cai X，Yang X，Lian F，et al.Correlation between serum anti-C1q antibody levels and renal pathological characteristics and prognostic significance of anti-C1q antibody in lupus nephritis.J Rheumatol，2010，37（4）：759-765.
18. Moroni G，Radice A，Giammarresi G，et al.Are laboratory tests useful for monitoring the activity of lupus nephritis？A 6-year prospective study in a cohort of 228 patients with lupus nephritis.Ann Rheum Dis，2009，68：234-237.
19. Yu F，Wu LH，Tan Y，et al.Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system.Kidney Int，2010，77：820-809.
20. Hsieh C，Chang A，Brandt D，et al.Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring.Arthritis Care Res，2011，63：865-874.
21. Ramos PS，Brown EE，Kimberly RP，et al.Genetic factors predisposing to systemic lupus erythematosus and lupus nephritis.Semin Nephrol，2010，30：164-176.
22. Bombardier C，Gladmman DD，Urowitz MB，et al.Derivation of the SLEDAI.A disease activity index for lupus patients.Arthritis rheum，1992，35（6）：630-640.
23. Kojo S，Sada KE，Kobayashi M，et al.Clinical usefulness of a prognostic score in histological analysis of renal biopsy in patients with lupus nephritis.J Rheumatol，2009，36：2218-2223.
24. AustinⅢHA，Muenz LR，Joyce KM，et al.Diffuse proliferative lupus nephritis：Identification of specific pathologic features affecting renal outcome.Kidney Int，1984，25 （4）：689-695.
25. Illei GG，Austin HA，Crane M，et al.Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.Ann Intern Med，2001，135：248-257.
26. Yee CS，Gordon C，Dostal C，et al.EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.Ann Rheum Dis，2004，63：525-529.
27. Ginzler EM，Dooley MA，Aranow C，et al.Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.N Engl J Med，2005，353：2219-2228.
28. Chen W，Tang X，Liu Q，et al.Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis：a multicenter randomized clinical trial.Am J Kidney Dis，2011，57：235-244.
29. Alarcón GS，McGwin G，Bertoli AM，et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus：data from LUMINA，a multiethnic US cohort（LUMINA L）.Ann Rheum Dis，2007，66：1168-1172.
30. Yap DY，Yu X，Chen XM，et al.Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome.Nephrology（Carlton），2012，17：352-357.
31. Navarra SV，Guzman RM，Gallacher AE，et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus：a randomised，placebo-controlled，phase 3 trial.Lancet，2011，377：721-731.
32. Bao H，Liu ZH，Xie HL，et al. Successful treatment of classⅤ+Ⅳlupus nephritis with multitarget therapy. J Am Soc Nephrol，2008，19（10）：2001-2010.
33. Dall’era M，Chakravarty EF.Treatment of mild，moderate，and severe lupus erythematosus：focus on new therapies.Curr Rheumatol Rep，2011，13（4）：308-316.